JPWO2022255460A1 - - Google Patents

Info

Publication number
JPWO2022255460A1
JPWO2022255460A1 JP2023525915A JP2023525915A JPWO2022255460A1 JP WO2022255460 A1 JPWO2022255460 A1 JP WO2022255460A1 JP 2023525915 A JP2023525915 A JP 2023525915A JP 2023525915 A JP2023525915 A JP 2023525915A JP WO2022255460 A1 JPWO2022255460 A1 JP WO2022255460A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023525915A
Other languages
Japanese (ja)
Other versions
JPWO2022255460A5 (https=
JP7700229B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022255460A1 publication Critical patent/JPWO2022255460A1/ja
Publication of JPWO2022255460A5 publication Critical patent/JPWO2022255460A5/ja
Application granted granted Critical
Publication of JP7700229B2 publication Critical patent/JP7700229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/501,3-Diazoles; Hydrogenated 1,3-diazoles
    • A01N43/521,3-Diazoles; Hydrogenated 1,3-diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01PBIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P7/00Arthropodicides
    • A01P7/04Insecticides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Insects & Arthropods (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023525915A 2021-06-02 2022-06-02 ベンゾイミダゾール化合物又はその塩類及び該化合物を含有する犬糸状虫症防除剤並びにその使用方法 Active JP7700229B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021092795 2021-06-02
JP2021092795 2021-06-02
JP2022021145 2022-02-15
JP2022021145 2022-02-15
PCT/JP2022/022536 WO2022255460A1 (ja) 2021-06-02 2022-06-02 ベンゾイミダゾール化合物又はその塩類及び該化合物を含有する犬糸状虫症防除剤並びにその使用方法

Publications (3)

Publication Number Publication Date
JPWO2022255460A1 true JPWO2022255460A1 (https=) 2022-12-08
JPWO2022255460A5 JPWO2022255460A5 (https=) 2024-03-11
JP7700229B2 JP7700229B2 (ja) 2025-06-30

Family

ID=84324302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525915A Active JP7700229B2 (ja) 2021-06-02 2022-06-02 ベンゾイミダゾール化合物又はその塩類及び該化合物を含有する犬糸状虫症防除剤並びにその使用方法

Country Status (14)

Country Link
US (1) US20240270712A1 (https=)
EP (1) EP4349824A4 (https=)
JP (1) JP7700229B2 (https=)
KR (1) KR20240012540A (https=)
AU (1) AU2022286144A1 (https=)
BR (1) BR112023024371A2 (https=)
CA (1) CA3222199A1 (https=)
CL (1) CL2023003509A1 (https=)
CO (1) CO2023017613A2 (https=)
MX (1) MX2023014032A (https=)
PH (1) PH12023553295A1 (https=)
UA (1) UA130072C2 (https=)
WO (1) WO2022255460A1 (https=)
ZA (1) ZA202311796B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022016546A (es) * 2020-07-03 2023-02-01 Nihon Nohyaku Co Ltd Agente anticoccidio y metodo para su uso.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524892A (ja) * 2007-04-19 2010-07-22 ノバルティス アーゲー 代謝型グルタミン酸受容体−5の修飾因子としてのニコチン酸誘導体
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Npy y5受容体拮抗作用を有するヘテロ環誘導体
JP2013522365A (ja) * 2010-03-23 2013-06-13 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経性疾患の検出のためのイメージング剤
CN108440396A (zh) * 2018-03-23 2018-08-24 吉林奥来德光电材料股份有限公司 一种有机发光材料及其制备方法和应用
WO2019049061A1 (en) * 2017-09-07 2019-03-14 Glaxosmithkline Intellectual Property Development Limited 5- (1H-BENZO [D] IMIDAZO-2-YL) -PYRIDIN-2-AMINE AND 5- (3H-IMIDAZO [4,5-B] PYRIDIN-6-YL) -PYRIDIN-2- DERIVATIVES AMINE AS HISTONE ACETYLTRANSFERASE INHIBITORS OF C-MYC AND P300 / CBP FOR THE TREATMENT OF CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
EP3798212A4 (en) * 2018-05-22 2022-03-23 Nihon Nohyaku Co., Ltd. BENZIMIDAZOLE COMPOUND OR SALT THEREOF, INSECTICIDE AND ACARICIDE FOR AGRICULTURE AND HORTICULTURE WITH THIS COMPOUND AND METHODS OF USE
MX2022016546A (es) * 2020-07-03 2023-02-01 Nihon Nohyaku Co Ltd Agente anticoccidio y metodo para su uso.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524892A (ja) * 2007-04-19 2010-07-22 ノバルティス アーゲー 代謝型グルタミン酸受容体−5の修飾因子としてのニコチン酸誘導体
JP2013522365A (ja) * 2010-03-23 2013-06-13 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経性疾患の検出のためのイメージング剤
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Npy y5受容体拮抗作用を有するヘテロ環誘導体
WO2019049061A1 (en) * 2017-09-07 2019-03-14 Glaxosmithkline Intellectual Property Development Limited 5- (1H-BENZO [D] IMIDAZO-2-YL) -PYRIDIN-2-AMINE AND 5- (3H-IMIDAZO [4,5-B] PYRIDIN-6-YL) -PYRIDIN-2- DERIVATIVES AMINE AS HISTONE ACETYLTRANSFERASE INHIBITORS OF C-MYC AND P300 / CBP FOR THE TREATMENT OF CANCER
CN108440396A (zh) * 2018-03-23 2018-08-24 吉林奥来德光电材料股份有限公司 一种有机发光材料及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, JPN6022031475, 2017, pages 3594 - 3605, ISSN: 0005469716 *
REGISTRY(STN)[ONLINE], JPN7024004914, 15 March 2021 (2021-03-15), pages 2024 - 11, ISSN: 0005469718 *
TETRAHEDRON LETTERS, vol. 49, no. 47, JPN6024046893, 2008, pages 6667 - 6669, ISSN: 0005469717 *

Also Published As

Publication number Publication date
CO2023017613A2 (es) 2024-01-15
WO2022255460A1 (ja) 2022-12-08
UA130072C2 (uk) 2025-10-29
KR20240012540A (ko) 2024-01-29
JP7700229B2 (ja) 2025-06-30
CA3222199A1 (en) 2022-12-08
MX2023014032A (es) 2023-12-15
BR112023024371A2 (pt) 2024-02-15
AU2022286144A1 (en) 2024-01-18
ZA202311796B (en) 2025-04-30
EP4349824A1 (en) 2024-04-10
CL2023003509A1 (es) 2024-05-17
US20240270712A1 (en) 2024-08-15
PH12023553295A1 (en) 2024-03-18
EP4349824A4 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
JPWO2022004877A1 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
JPWO2022255460A1 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250618

R150 Certificate of patent or registration of utility model

Ref document number: 7700229

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150